It is now clear that reactive oxygen species (ROS) can act as signalling molecules in the cerebral circulation under both physiological and pathological conditions. Some major products of superoxide (O2•−) metabolism, such as hydrogen peroxide (H2O2) and hydroxyl radical (OH•), appear to be particularly good cerebral vasodilators and may, surprisingly, represent important molecules for increasing local cerebral blood flow.
A major determinant of overall ROS levels in the cerebral circulation is the rate of generation of the parent molecule, O2•−. Although the major enzymatic source of O2•− in cerebral arteries is yet to be conclusively established, the two most likely candidates are cyclo-oxygenase and nicotinamide adenine dinucleotide phosphate (reduced form) [NADPH] oxidase. The activity of endogenous superoxide dismutases (SODs) play a vital role in determining levels and effects of all individual ROS derived from metabolism of O2•−.
The term ‘oxidative stress’ may be an over-simplification that hides the complexity and diversity of the ROS family in cerebrovascular health and disease. Although a generalised increase in ROS levels seems to occur during several vascular disease states, the consequences of this for cerebrovascular function are still unclear.
Because enhanced breakdown of O2•− by SOD will increase the generation of the powerful cerebral vasodilator H2O2, this latter molecule could conceivably act as a compensatory vasodilator mechanism in the cerebral circulation under conditions of elevated O2•− production.
Some recent clinical data support the concept of a protective role for cerebrovascular NADPH oxidase activity. Although it is quite speculative at present, if NADPH oxidase were to emerge as a major source of beneficial vasodilator ROS in the cerebral circulation, this may represent a significant dilemma for treatment of ischaemic cerebrovascular conditions, as excessive NADPH oxidase activity is associated with the progression of several systemic vascular disease states, including hypertension and atherosclerosis.
Despite data suggesting that antioxidant vitamins can have beneficial effects on vascular function and that their plasma levels are inversely correlated with risk of cardiovascular disease and stroke, the results of several recent large-scale clinical trials of antioxidant supplementation have been disappointing.
Future work must establish whether or not increased ROS generation is necessarily detrimental to cerebral vascular function, as has been generally assumed, or whether localised increases in ROS in the vicinity of the arterial wall could be beneficial in disease states for the maintenance of cerebral blood flow.
Reactive Oxygen Species NADPH Oxidase Xanthine Oxidase Reactive Oxygen Species Level Cerebral Vasospasm
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Dr Sobey is supported by an R.D. Wright Fellowship (209160) from the National Health and Medical Research Council of Australia (NHMRC). Dr Drummond is supported by a NHMRC Peter Doherty Postdoctoral Fellowship (007044). Ms Paravicini is supported by an Australian Postgraduate Award from the Australian Government.
Dr Sobey and Dr Drummond hold equity in Radical Biotechnology Pty Ltd, a University of Melbourne-based company developing drugs to treat cardiovascular diseases. Dr Sobey is a Director of this company. Neither author receives commission or any direct income from this company.
Rosenblum WI. Effects of free radical generation on mouse pial arterioles: probable role of hydroxyl radicals. Am J Physiol1983; 245(1): H139–42PubMedGoogle Scholar
Wei EP, Christman CW, Kontos HA, et al. Effects of oxygen radicals on cerebral arterioles. Am J Physiol 1985; 248 (2 Pt 2): H157–62PubMedGoogle Scholar
Leffler CW, Busija DW, Armstead WM, et al. H2O2 effects on cerebral prostanoids and pial arteriolar diameter in piglets. Am J Physiol1990; 258 (5 Pt 2): H1382–7PubMedGoogle Scholar
Wei EP, Kontos HA. H2O2 and endothelium-dependent cerebral arteriolar dilation: implications for the identity of endothelium-derived relaxing factor generated by acetylcholine. Hypertension 1990; 16(2): 162–9PubMedCrossRefGoogle Scholar
Iida Y, Katusic ZS. Mechanisms of cerebral arterial relaxations to hydrogen peroxide. Stroke 2000; 31(9): 2224–30PubMedCrossRefGoogle Scholar
Sobey CG, Heistad DD, Faraci FM. Potassium channels mediate dilatation of cerebral arterioles in response to arachidonate. Am J Physiol 1998; 275 (5 Pt 2): H1606–12PubMedGoogle Scholar
Sobey CG, Heistad DD, Faraci FM. Mechanisms of bradykinin-induced cerebral vasodilatation in rats: evidence that reactive oxygen species activate K+ channels. Stroke 1997; 28(11): 2290–4PubMedCrossRefGoogle Scholar
Wei EP, Kontos HA, Beckman JS. Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite. Am J Physiol 1996; 271(3 Pt 2): H1262–6PubMedGoogle Scholar
Wolin MS. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol 2000; 20(6): 1430–42PubMedCrossRefGoogle Scholar
Skinner KA, White CR, Patel R, et al. Nitrosation of uric acid by peroxynitrite: formation of a vasoactive nitric oxide donor. J Biol Chem 1998; 273(38): 24491–7PubMedCrossRefGoogle Scholar
Kontos HA, Wei EP, Povlishock JT, et al. Oxygen radicals mediate the cerebral arteriolar dilation from arachidonate and bradykinin in cats. Circ Res 1984; 55(3): 295–303PubMedCrossRefGoogle Scholar
Rosenblum WI. Hydroxyl radical mediates the endothelium-dependent relaxation produced by bradykinin in mouse cerebral arterioles. Circ Res 1987; 61(4): 601–3PubMedCrossRefGoogle Scholar
Ellis EF, Police RJ, Yancey L, et al. Dilation of cerebral arterioles by cytochrome P-450 metabolites of arachidonic acid. Am J Physiol 1990; 259 (4 Pt 2): H1171–7PubMedGoogle Scholar
Yang ST, Mayhan WG, Faraci FM, et al. Mechanisms of impaired endothelium-dependent cerebral vasodilatation in response to bradykinin in hypertensive rats. Stroke 1991; 22(9): 1177–82PubMedCrossRefGoogle Scholar
Matoba T, Shimokawa H, Nakashima M, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 2000; 106(12): 1521–30PubMedCrossRefGoogle Scholar
Matoba T, Shimokawa H, Kubota H, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun 2002; 290(3): 909–13PubMedCrossRefGoogle Scholar
Yada T, Shimokawa H, Hiramatsu O, et al. Hydrogen peroxide, an endogenous endothelium-derived hyperpolarizing factor, plays an important role in coronary autoregulation in vivo. Circulation 2003; 107(7): 1040–5PubMedCrossRefGoogle Scholar
Matoba T, Shimokawa H, Morikawa K, et al. Electron spin resonance detection of hydrogen peroxide as an endothelium-derived hyperpolarizing factor in porcine coronary microvessels. Arterioscler Thromb Vasc Biol 2003; 23(7): 1224–30PubMedCrossRefGoogle Scholar
Morikawa K, Shimokawa H, Matoba T, et al. Pivotal role of Cu,Zn-superoxide dismutase in endothelium-dependent hyper-polarization. J Clin Invest 2003; 112(12): 1871–9PubMedGoogle Scholar
Didion SP, Hathaway CA, Faraci FM. Superoxide levels and function of cerebral blood vessels after inhibition of CuZn-SOD. Am J Physiol Heart Circ Physiol 2001; 281(4): H1697–703PubMedGoogle Scholar
Griendling KK, Sorescu D, Ushio-Fukai M. NAD (P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86(5): 494–501PubMedCrossRefGoogle Scholar
Landino LM, Crews BC, Timmons MD, et al. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci U S A 1996; 93(26): 15069–74PubMedCrossRefGoogle Scholar
Bengtsson SHM, Gulluyan LM, Dusting GJ, et al. Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology. Clin Exp Pharmacol Physiol 2003; 30: 849–54PubMedCrossRefGoogle Scholar
Lassegue B, Sorescu D, Szocs K, et al. Novel gp91 (phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001; 88(9): 888–94PubMedCrossRefGoogle Scholar
Sorescu D, Weiss D, Lassegue B, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002; 105(12): 1429–35PubMedCrossRefGoogle Scholar
Ago T, Kitazono T, Ooboshi H, et al. Nox4 as the major catalytic component of an endothelial NAD (P)H oxidase. Circulation 2004; 109: 227–33PubMedCrossRefGoogle Scholar
De Keulenaer GW, Chappell DC, Ishizaka N, et al. Oscillatory and steady laminar shear stress differentially affect human endothelial redox state: role of a superoxide-producing NADH oxidase. Circ Res 1998; 82(10): 1094–101PubMedCrossRefGoogle Scholar
Paravicini TM, Chrissobolis S, Drummond GR, et al. Increased NADPH-oxidase activity and Nox4 expression during chronic hypertension is associated with enhanced cerebral vasodilatation to NADPH in vivo. Stroke 2004; 35(2): 584–9PubMedCrossRefGoogle Scholar
Didion SP, Faraci FM. Effects of NADH and NADPH on superoxide levels and cerebral vascular tone. Am J Physiol Heart Circ Physiol 2002; 282(2): H688–95PubMedGoogle Scholar
Beetsch JW, Park TS, Dugan LL, et al. Xanthine oxidase-derived superoxide causes reoxygenation injury of ischemic cerebral endothelial cells. Brain Res 1998; 786(1–2): 89–95PubMedCrossRefGoogle Scholar
Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD (P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105(14): 1656–62PubMedCrossRefGoogle Scholar
Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111(8): 1201–9PubMedGoogle Scholar
Alp NJ, Channon KC. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1–9CrossRefGoogle Scholar
Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in ApoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001; 103(9): 1282–8PubMedCrossRefGoogle Scholar
Stralin P, Karlsson K, Johansson BO, et al. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol 1995; 15(11): 2032–6PubMedCrossRefGoogle Scholar
Didion SP, Ryan MJ, Didion LA, et al. Increased superoxide and vascular dysfunction in CuZnSOD-deficient mice. Circ Res 2002; 91(10): 938–44PubMedCrossRefGoogle Scholar
Mayhan WG. Superoxide dismutase partially restores impaired dilatation of the basilar artery during diabetes mellitus. Brain Res 1997; 760(1–2): 204–9PubMedCrossRefGoogle Scholar
Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001; 21(1): 2–14PubMedCrossRefGoogle Scholar
Leppala JM, Virtamo J, Fogelholm R, et al. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke 1999; 30(12): 2535–40PubMedCrossRefGoogle Scholar
Faraci FM, Heistad DD. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol Rev 1998; 78(1): 53–97PubMedGoogle Scholar
Walder CE, Green SP, Darbonne WC, et al. Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. Stroke 1997; 28(11): 2252–8PubMedCrossRefGoogle Scholar
Ito D, Murata M, Watanabe K, et al. C242T polymorphism of NADPH oxidase p22 PHOX gene and ischemic cerebrovascular disease in the Japanese population. Stroke 2000; 31(4): 936–9PubMedCrossRefGoogle Scholar
Guzik TJ, West NE, Black E, et al. Functional effect of the C242T polymorphism in the NAD (P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000; 102(15): 1744–7PubMedCrossRefGoogle Scholar
Chamorro A, Vila N, Ascaso C, et al. Blood pressure and functional recovery in acute ischemic stroke. Stroke 1998; 29(9): 1850–3PubMedCrossRefGoogle Scholar
Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52(4): 639–72PubMedGoogle Scholar
Wei EP, Kontos HA, Patterson Jr JL. Vasoconstrictor effect of angiotensin on pial arteries. Stroke 1978; 9(5): 487–9PubMedCrossRefGoogle Scholar
Haberl RL, Anneser F, Villringer A, et al. Angiotensin II induces endothelium-dependent vasodilation of rat cerebral arterioles. Am J Physiol 1990; 258 (6 Pt 2): H1840–6PubMedGoogle Scholar
Haberl RL. Role of angiotensin receptor subtypes in the response of rabbit brain arterioles to angiotensin. Stroke 1994; 25(7): 1476–9PubMedCrossRefGoogle Scholar
Didion SP, Sigmund CD, Faraci FM. Impaired endothelial function in transgenic mice expressing both human renin and human angiotensinogen. Stroke 2000; 31(3): 760–4PubMedCrossRefGoogle Scholar
Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996; 97(8): 1916–23PubMedCrossRefGoogle Scholar
Touyz RM, Chen X, Tabet F, et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD (P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 2002; 90(11): 1205–13PubMedCrossRefGoogle Scholar
Didion SP, Faraci FM. Angiotensin II produces superoxide-mediated impairment of endothelial function in cerebral arterioles. Stroke 2003; 34(8): 2038–42PubMedCrossRefGoogle Scholar
Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324(7339): 699–702PubMedCrossRefGoogle Scholar
Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22(9): 391–7PubMedCrossRefGoogle Scholar
Liu TH, Beckman JS, Freeman BA, et al. Polyethylene glycolconjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol Heart Circ Physiol 1989; 256(2): H589–93Google Scholar
Kinouchi H, Epstein C, Mizui T, et al. Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc Natl Acad Sci U S A 1991; 88(24): 11158–62PubMedCrossRefGoogle Scholar
Yang G, Chan PH, Chen J, et al. Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke 1994; 25(1): 165–70PubMedCrossRefGoogle Scholar
Kondo T, Reaume AG, Huang TT, et al. Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J Neurosci 1997; 17(11): 4180–9PubMedGoogle Scholar
Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4(5): 399–415PubMedCrossRefGoogle Scholar
Sobey CG, Faraci FM. Subarachnoid haemorrhage: what happens to the cerebral arteries? Clin Exp Pharmacol Physiol 1998; 25(11): 867–76PubMedCrossRefGoogle Scholar
Mori T, Nagata K, Town T, et al. Intracisternal increase of superoxide anion production in a canine subarachnoid hemorrhage model. Stroke 2001; 32(3): 636–42PubMedCrossRefGoogle Scholar
Kim DE, Suh YS, Lee MS, et al. Vascular NAD (P)H oxidase triggers delayed cerebral vasospasm after subarachnoid hemorrhage in rats. Stroke 2002; 33(11): 2687–91PubMedCrossRefGoogle Scholar
Watanabe Y, Chu Y, Andresen JJ, et al. Gene transfer of extracellular superoxide dismutase reduces cerebral vasospasm after subarachnoid hemorrhage. Stroke 2003; 34(2): 434–40PubMedCrossRefGoogle Scholar
Yamaguchi T, Sano K, Takakura K, et al. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 1998; 29(1): 12–7Google Scholar
Cherubini A, Polidori MC, Bregnocchi M, et al. Antioxidant profile and early outcome in stroke patients. Stroke 2000; 31(10): 2295–300PubMedCrossRefGoogle Scholar
Leinonen JS, Ahonen JP, Lonnrot K, et al. Low plasma antioxidant activity is associated with high lesion volume and neurological impairment in stroke. Stroke 2000; 31(1): 33–9PubMedCrossRefGoogle Scholar
Gale CR, Martyn CN, Winter PD, et al. Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. BMJ 1995; 310(6994): 1563–6PubMedCrossRefGoogle Scholar
Yokoyama T, Date C, Kokubo Y, et al. Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community. The Shibata Study. Stroke 2000; 31(10): 2287–94Google Scholar
Svetkey LP, Loria CM. Blood pressure effects of vitamin C: what’s the key question? Hypertension 2002; 40(6): 789–91PubMedCrossRefGoogle Scholar
Kurl S, Tuomainen TP, Laukkanen JA, et al. Plasma vitamin C modifies the association between hypertension and risk of stroke. Stroke 2002; 33(6): 1568–73PubMedCrossRefGoogle Scholar
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 23–33CrossRefGoogle Scholar
Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 154–60PubMedCrossRefGoogle Scholar
Landmesser U, Harrison DG. Oxidant stress as a marker for cardiovascular events: Ox marks the spot. Circulation 2001; 104(22): 2638–40PubMedGoogle Scholar
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53PubMedCrossRefGoogle Scholar
Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35(3): 776–85PubMedCrossRefGoogle Scholar
Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995–1003PubMedCrossRefGoogle Scholar